医学
动态血压
重症监护医学
血管紧张素受体阻滞剂
螺内酯
心脏病学
内科学
血压
疾病
回廊的
血管紧张素转换酶
药物治疗
药丸
药理学
心力衰竭
作者
Sofie Brouwers,Isabella Sudano,Yoshihiro Kokubo,Elisabeth M. Sulaica
出处
期刊:The Lancet
[Elsevier BV]
日期:2021-05-18
卷期号:398 (10296): 249-261
被引量:176
标识
DOI:10.1016/s0140-6736(21)00221-x
摘要
Arterial hypertension is the most important contributor to the global burden of disease; however, disease control remains poor. Although the diagnosis of hypertension is still based on office blood pressure, confirmation with out-of-office blood pressure measurements (ie, ambulatory or home monitoring) is strongly recommended. The definition of hypertension differs throughout various guidelines, but the indications for antihypertensive therapy are relatively similar. Lifestyle adaptation is absolutely key in non-pharmacological treatment. Pharmacologically, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, and diuretics are the first-line agents, with advice for the use of single-pill combination therapy by most guidelines. As a fourth-line agent, spironolactone should be considered. The rapidly evolving field of device-based therapy, especially renal denervation, will further broaden therapeutic options. Despite being a largely controllable condition, the actual rates of awareness, treatment, and control of hypertension are disappointingly low. Further improvements throughout the process of patient screening, diagnosis, treatment, and follow-up need to be urgently addressed.
科研通智能强力驱动
Strongly Powered by AbleSci AI